Adenovirus-vectored Ebola vaccines.
The 2014 outbreak of Ebola virus disease in West Africa has highlighted the need for the availability of effective vaccines against outbreak pathogens that are suitable for use in frontline workers who risk their own health in the course of caring for those with the disease, and also for members of the community in the affected area. Along with effective contact tracing and quarantine, use of a vaccine as soon as an outbreak is identified could greatly facilitate rapid control and prevent the outbreak from spreading. This review describes the progress that has been made in producing and testing adenovirus-based Ebola vaccines in both pre-clinical and clinical studies, and considers the likely future use of these vaccines.
a University of Oxford, The Jenner Institute, ORCRB, Oxford OX3 7DQ, UK.
Sarah C
SC
Gilbert
D000256:Adenoviridae / Q000235:genetics / Q000276:immunology*; D017954:Africa South of the Sahara; D057134:Antibodies, Neutralizing / Q000276:immunology*; D000914:Antibodies, Viral / Q000276:immunology*; D004196:Disease Outbreaks / Q000517:prevention & control; D046129:Ebola Vaccines / Q000276:immunology*; D029043:Ebolavirus / Q000276:immunology*; D019142:Hemorrhagic Fever, Ebola / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D006801:Humans; D014611:Vaccination
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D046129:Ebola Vaccines
Ebola virus disease; clinical trials; outbreak pathogen; replication-deficient adenoviral vector; response to vaccination; simian adenoviral vector; vaccination